Vivos Therapeutics (VVOS) Invested Capital (2019 - 2025)
Historic Invested Capital for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $2.9 million.
- Vivos Therapeutics' Invested Capital fell 6254.4% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 6254.4%. This contributed to the annual value of $8.0 million for FY2024, which is 183527.98% up from last year.
- Per Vivos Therapeutics' latest filing, its Invested Capital stood at $2.9 million for Q3 2025, which was down 6254.4% from $4.7 million recorded in Q2 2025.
- Vivos Therapeutics' Invested Capital's 5-year high stood at $37.7 million during Q2 2021, with a 5-year trough of $46000.0 in Q3 2023.
- Its 5-year average for Invested Capital is $11.0 million, with a median of $7.0 million in 2023.
- Its Invested Capital has fluctuated over the past 5 years, first tumbled by 9953.32% in 2023, then skyrocketed by 1656304.35% in 2024.
- Quarter analysis of 5 years shows Vivos Therapeutics' Invested Capital stood at $26.8 million in 2021, then crashed by 82.09% to $4.8 million in 2022, then crashed by 91.44% to $411000.0 in 2023, then skyrocketed by 1835.28% to $8.0 million in 2024, then crashed by 63.9% to $2.9 million in 2025.
- Its Invested Capital stands at $2.9 million for Q3 2025, versus $4.7 million for Q2 2025 and $4.4 million for Q1 2025.